Member Info for Timster

the usual ****** to building up all avacta meetings occurred. it's an agm which was never going to cause a massive uplift in sp.

Interesting confirmation that they won't wait till the end of 1b to announce efficacy.

So all though the end point is 12-18 months I'm sure we will get some juicy information along the way.

I've got plenty of time to see this through, and will be happy to top up when I can.

And he acknowledged it needs the human miracle cure angle for the mainstream media.

Good to hear the PK data will be published in the mainstream journals after p1a.

Good resistance to soggyness

Not what he said....

SP will do what it does driven by time scales I don't really care, Avacta clearly know what they have, they clearly have had lots of interesting meetings with the pharma world due to the in patient data.

Some good questions there too, answered by Alistair.

And who knew dox is definitely dox when cleaved from ava6k

Very very happy with that presentation if I had the funds to chomp I would....

Yet you won't be there at the Q&A session to express your concerns. I guess you must have emailed Alan though?

I'm very concerned there hasn't been any updates on the biscuits and coffee inflection point which began at 10.15

As an investor it's incredibly worrying....

Side effects, seen through the cohorts, no MTD?

Think eggy, what you are peddling is utter bollax

What an absolute moron eggy is.

I've read some more:

Dose Escalation

• AVA6000 has a modest and predictable safety profile across the dose range (80-200mg/m2)

• PK data for released doxorubicin highlights a positive profile

• Doxorubicin Exposure (AUC) & Maximal Concentrations (Cmax) substantially reduced across doses

• Doxorubicin concentrations are higher in tumour biopsies compared to plasma at 24 hrs timepoint

• Emerging PK profiles offer the opportunity to increase dosing duration & intensity of doxorubicin targeted to the

tumour

• Confidence in Development Strategy for AVA6000 in 1st Line Soft Tissue Sarcoma (STS)

• Advanced, Metastatic STS tumours are known to be highly FAP positive

• Doxorubicin monotherapy is the only therapy indicated for first-line advanced, metastatic STS

• Large unmet clinical need in STS to improve patients outcomes in difficult to treat tumours

• AVA6000 preferentially targets the tumour environment using FAP specificity to activate doxorubicin

• AVA6000 can safely deliver larger doses of doxorubicin to tumour whilst sparing healthy tissues and organs.

I'm crapping myself now, you are right is sounds terrible.... 🤡🤡🤡

Wtf are you talking about?? It's working exactly as it should, from today's presentation:

Doxorubicin concentrations are higher in tumour biopsies compared to plasma at 24 hrs timepoint

Expecting NY size

The fud getting more desperate and making you look more stupid per post.

Give it up eggy you are pathetic...

"If tissue levels with AVA6000 are unlikely to match those achieved by current Doxorubicin regimes"

Really??? Moron...

I'm no clinician but does phase 1b sound a bit more than your standard phase 1b (like if Carlsberg did it)

Potential Primary Endpoints

1. Progression-free survival.

2. Safety & tolerability.

Potential Secondary Endpoints

1. Percentage of patients who are progression-free at 3 months.

2. Pharmacokinetics (AVA6000/Doxorubicin).

3. Objective Response Rate (ORR).

4. Doxorubicin levels in mandatory biopsies

Looks pretty good Joe.

Nice